NOTTINGHAM, UK. — January 9th, 2019 — CHAIN has joined EuropaBio as a full member after placing runner-up in the Biotech SME Awards announced in November. As part of this membership, CHAIN gains access to EuropaBio’s network and will receive updates from working groups operating in diverse areas such as IP, regulatory policy and personalised medicine.
The awards ceremony in Brussels was held on December 3rd where MEP Paul Rübig, who sits on the Committee for Industry, Research and Energy, hosted the awards ceremony. CHAIN Chief Executive Dr Edward Green represented the company giving a presentation. On becoming a member of EuropaBio, Dr Green said, “CHAIN is delighted to be recognised by the EuropaBio SME Awards; we are an early stage UK-based microbiome therapeutics company, so recognition on the European stage is a big boost for us and validation of our innovative technology platform. We hope recognition will raise awareness of CHAIN’s novel and highly differentiated approach to use superior live biotherapeutics to treat chronic and debilitating gut related diseases.”
EuropaBio is the largest biotech advocacy group in Europe, with members including national biotech organisations like the UK’s BioIndustry Association, industry giants Merck and Bayer, and SMEs. EuropaBio are implementing an SME platform where companies can attend workshops and webinars dedicated to providing advice and helping their development.
CHAIN Biotechnology is a UK microbiome company focused on the development and commercialisation of microbial technology for the production and delivery of biotherapeutics to the gut. The company’s microbial technology has the potential to be highly disruptive both in terms of cost but also efficacy for the treatment and prevention of chronic and debilitating gut related diseases. CHAIN was founded in 2014 by serial entrepreneur Dr Edward Green. The Company has bases in Marlow (Head office) and MediCity Nottingham (Research Lab).
Dr David Kirk
Senior Scientist, CHAIN Biotechnology Ltd
Phone Number: +44 (0) 115 784 0106
CHAIN features in a new explainer document on engineering biology from the UK Bioindustry Association (BIA) published today. Engineering Biology Explained discusses what these areas are all about, showcasing the important contributions made to these industries by UK bioscience companies and outlining the external environment required to ensure that these areas of innovation continue to benefit patients, the economy and society as a whole.
CHAIN’s contribution to the piece focuses on our novel CADD drug delivery platform, exemplified by our lead product which delivers R-3-hydroxybutyrate to the large intestine. This report is part of a series of four, covering the issues of antimicrobial resistance, cell and gene therapy, engineering biology and genomics. The engineering biology report was published alongside one covering cell and gene therapy. The reports on antimicrobial resistance and genomics will be published later in October 2018.
UK biotech to manufacture novel medicines for Inflammatory Bowel Disease using spores of gut bacteria
Three leading British biotechnology businesses have obtained grant funding from Innovate UK to investigate the manufacture of a new class of medicines, targeting a range of clinical conditions through interaction with the human microbiome.
The novel and highly innovative approach is to use spores derived from anaerobic bacteria (Clostridia) that are naturally found in our large intestines to deliver targeted anti-inflammatory therapeutics. Bacterial spores are resistant to acid, so when ingested in a tablet or capsule they are able to pass largely unscathed through the stomach before germinating and releasing the anti-inflammatory bio-actives (payload) to where it is needed in the colon, to treat chronic and debilitating inflammatory conditions, such as Ulcerative Colitis and Crohn’s Disease.
The concept has been proven in pre-clinical tests by the project consortium lead CHAIN Biotechnology, but until now a stumbling block has been the lack of a biopharmaceutical manufacturing facility in the UK, able to scale-up and manufacture Clostridial spore-based medicines to the required standard, following good manufacturing practice (GMP), needed for medicinal products for human testing and use. This is where Porton Biopharma with its knowledge and history of developing and producing bio-therapeutics from various spore-forming bacteria, and Scitech which specialises in design, engineering, construction and validation of facilities within the life-science sector will add their expertise.
Developing and testing the technological approach of microbiome targeted therapeutics, and being first in the market with an advanced medicine manufacturing capability and capacity required for such products, would see CHAIN Biotechnology and the UK taking a step closer to becoming world-leaders in this fast growing emerging health care area.
Dr Basil Omar CHAIN’s Co-Founder and Chief Commercial Officer said “The output of this feasibility project will support the business case for further investment in a dedicated, advanced manufacturing facility for these breakthrough therapeutic products offering medical treatments and delivering real benefits for long-suffering patients”.
Dr Roger Hinton MD of Porton Biopharma said “This is an ideal fit for us given our history of developing biopharmaceuticals from spore formers, knowledge of GMP manufacture and specialised containment microbiology. We are very excited by the commercial potential.”
Dave Grant MD of Scitech said “Life sciences are an essential part of the UK government’s new industrial strategy and this award facilitates the creation of much needed new specialist manufacturing industrial infrastructure with new highly-skilled jobs”.
Note to editors:
CHAIN Biotechnology Limited was founded in 2014, by serial entrepreneur Dr Edward Green, to exploit the therapeutic potential of Clostridia bacteria found in the human gut microbiome. CHAIN’s innovative platform technology supports a product pipeline, developed through the identification and delivery of small molecules, peptides and natural metabolites that interact positively with the gut microbiome. CHAIN is targeting a broad range of clinical conditions including control of infection and inflammation in the gut as well as interacting with signalling receptors in the gut which have an effect on the Central Nervous System, with potential new treatments for such conditions as depression and neurological disorders.
Porton Biopharma Limited (PBL) manufactures a number of biopharmaceutical products including the UK’s anthrax vaccine and Erwinase®, a treatment for childhood leukaemia. It has state-of-the-art cGMP pharmaceutical manufacturing facilities which are licensed by the MHRA & FDA and employs approximately 300 people. PBL is registered in England and Wales under company number 9331560. It was commercialised from Public Health England (PHE) in 2015 to enable it to be better placed to develop the business of developing & manufacturing life-saving biopharmaceutical products.
Scitech Engineering Ltd are specialists in design, engineering, construction and validation for the pharmaceutical, biotechnology and life science sectors. Formed in 2002 Scitech is an employee owned, highly specialised and skilled business offering a full range of engineering, construction and professional services.
Inflammatory Bowel Disease (IBD) is a chronic and debilitating set of diseases characterised by inflammation in the lower digestive tract. The most common conditions are Ulcerative Colitis and Crone’s Disease. In the EU, IBD affects 2.6M people with annual healthcare costs of >£4.5Bn. IBD is more common in industrialised nations although incidence is rapidly increasing globally, driven by pursuit of ‘westernised’ lifestyles in developing countries.
Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. For further information visit www.innovateuk.gov.uk
For more information contact
CHAIN Biotech: Dr Basil Omar, Chief Commercial Officer on 0777 166 0800 firstname.lastname@example.org
Porton Biopharma: Dr Phil Luton, Commercial & marketing Manager on 01980 619723 or 07342 056193 email@example.com
Scitech: Rachel Slater, Business Development Manager on 01483 270 524 firstname.lastname@example.org